Table 4

Student's t-test (paired) analyses for comparison of the scores obtained from the low-dose and high-dose 5-Loxin® groups at day 90

n
 Baseline
 Day 90
 95% CI (versus placebo)
 P


Mean
 SD
 Mean
 SD

Visual analogue scale score
     Placebo
 23
 56.88
 12.04
 41.76
 15.98
<0.05
     100 mg 5-Loxin®
 24
 57.05
 8.71
 21.37
 7.13
 -27.67, -13.11
 <0.0001
     250 mg 5-Loxin®
 23
 55.62
 9.26
 14.22
 6.8
 -34.94, -20.19
 <0.0001
Lequesne's Functional Index
     Placebo
 23
 12.76
 2.6
 10.19
 3.24
0.031
     100 mg 5-Loxin®
 24
 12.1
 2.76
 7.78
 4.61
 -4.74, -0.07
 <0.0001
     250 mg 5-Loxin®
 23
 12.04
 3.03
 7
 3.5
 -5.19, -1.18
 <0.0001
WOMAC pain subscale
     Placebo
 23
 38.04
 2.03
 31.74
 2.58
0.1212
     100 mg 5-Loxin®
 24
 42.08
 2.93
 19.17
 3.55
 -21.33, to -3.83
 <0.0001
     250 mg 5-Loxin®
 23
 37.17
 2.88
 15.22
 2.50
 -23.78 to -9.28
 <0.0001
WOMAC stiffness subscale
     Placebo
 23
 33.15
 2.73
 24.45
 2.37
0.2983
     100 mg 5-Loxin®
 24
 31.77
 3.61
 14.06
 3.71
 -38.87, -6.85
 <0.0001
     250 mg 5-Loxin®
 23
 27.72
 3.44
 9.24
 2.07
 -43.35, -17.45
 <0.0001
WOMAC function subscale
     Placebo
 23
 41.30
 2.02
 34.07
 1.09
0.1048
     100 mg 5-Loxin®
 24
 41.48
 2.31
 24.32
 4.28
 -18.64, -0.82
 <0.0001
     250 mg 5-Loxin®
 23
 38.56
 2.32
 17.267
 1.98
 -21.39, -12.23
 <0.0001
MMP-3 (ng/ml)
     Placebo
 15
 902.1
 275.6
 928.5
 216.02
0.4886
     100 mg 5-Loxin®
 16
 893.6
 270.1
 637.2
 224.5
<0.0001
     250 mg 5-Loxin®
 14
 926.9
 270.5
 497.5
 167.5
<0.0001

CI, confidecne interval; MMP, matrix metalloproteinase; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

Sengupta et al. Arthritis Research & Therapy 2008 10:R85   doi:10.1186/ar2461